Physician profile
Sayed Monis
NPI 1942480231
$8,221.67
in general payments reported to CMS, 2019-2025
30 companies · $1,260 in 2025
The $1,260 reported for 2025 was more than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $724 · 2020: $351 · 2021: $1,027 · 2022: $1,838 · 2023: $2,085 · 2024: $937 · 2025: $1,260.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,281.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,281.31 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $3,383.91 | 2021-2024 | Intellis Adaptivestim, Vanta Adaptivestim |
| Nevro Corp. | $1,115.34 | 2023-2024 | Senza |
| Globus Medical, INC. | $918.13 | 2025 | Senza, Omnia, Affix |
| Medtronic USA, INC. | $530.41 | 2019-2020 | |
| Mdd US Operations, LLC | $392.63 | 2023-2025 | Gocovri, Gocovri, Qelbree |
| Abbvie INC. | $267.67 | 2021-2024 | |
| Teva Pharmaceuticals USA, INC. | $185.66 | 2019-2021 | |
| Biogen, INC. | $162.19 | 2021-2022 | |
| Grt US Holding, INC. | $162.00 | 2022 | |
| Acadia Pharmaceuticals INC | $153.67 | 2019-2024 | Nuplazid |
| Neurocrine Biosciences, INC. | $118.03 | 2023-2025 | Ingrezza |
| Stimwave Technologies Incorporated | $115.60 | 2022 | |
| Boston Scientific Corporation | $92.40 | 2019-2020 | |
| Biohaven Pharmaceutical Holding Company Ltd. | $89.61 | 2022 | |
| Sunovion Pharmaceuticals INC. | $86.08 | 2019-2020 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neurelis, INC. | $84.10 | 2020-2023 | Valtoco |
| Allergan, INC. | $50.59 | 2020 | |
| Otsuka America Pharmaceutical, INC. | $42.40 | 2025 | Rexulti |
| Amgen INC. | $33.41 | 2022 | |
| Pfizer INC. | $31.00 | 2023-2025 | |
| Astrazeneca Pharmaceuticals Lp | $25.49 | 2021 | |
| Amneal Pharmaceuticals LLC | $25.44 | 2024 | Rytary |
| Lilly USA, LLC | $24.86 | 2020 | |
| Vertex Pharmaceuticals Incorporated | $22.76 | 2025 | |
| Corium, LLC | $21.96 | 2022 | |
| Emd Serono, INC. | $21.58 | 2019 | |
| Spr Therapeutics, INC | $21.42 | 2025 | Sprint Pns System |
| Eisai INC. | $15.50 | 2023 | |
| Nalu Medical, INC. | $14.02 | 2025 | Nalu Neurostimulation System |
| Supernus Pharmaceuticals, INC. | $13.81 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sayed Monis listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.